Last updated on November 2017

Alpha 1 Antitrypsin Deficiency


Brief description of study

Alpha 1 Antitrypsin Deficiency

Detailed Study Description

A stage 1, prospective, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of Alpha 1-proteinase Inhibitor (A1P1) augmentation therapy in subjects with A1P1 Deficiency and chronic obstructive pulmonary disease (COPD).

This study is an approximately 2 year study that will evaluate the safety and effectiveness of the FDA approved drugs Aralast NP and Glassia in COPD patients with Alpha 1 Antitrypsin Deficiency compared to placebo.

Clinical Study Identifier: TX9661

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Customer Service

Phoenix Medical Research
Peoria, AZ USA
  Connect »